Ast-201
Liver And Intrahepatic Bile Duct Neoplasm
Explore 21 assets in Liver And Intrahepatic Bile Duct Neoplasm →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Aptamer Sciences, Inc.
Modality
vaccine
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06687941CT.gov A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver And Intrahepatic Bile Duct Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ast-201 (this asset) | Aptamer Sciences, Inc. | P1 | CC · 43 |
| Irinotecan | Tehran University of Medical Sciences | P4 | BBB |
| Albumin Aggregated | Sirtex Medical | P4 | BB |
| Chlorhexidine | Changhua Christian Hospital | P4 | BB |
| Talaporfin | Light Sciences Oncology | P3 | BB |
| Oxaliplatin | Shanghai Zhongshan Hospital | P4 | BB |
| Fluorouracilum | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P4 | BB |
| Hep-V Vax | University of Oxford | P4 | BB |
| Indocyanine Green | Hospital Universitari Vall d'Hebron Research Institute | P4 | BB |
+41 more in the Liver And Intrahepatic Bile Duct Neoplasm cohort
Other indications for Ast-201
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Cancer | — | P2 | CCC · 53 |
| Hepatocellular Carcinoma | — | P1 | CC · 41 |
| Neoplasm | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ast-201 in Liver And Intrahepatic Bile Duct Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ast-201-liver-and-intrahepatic-bile-duct-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →